Calidi Biotherapeutics closes $3.9M registered direct offering and private placement

Calidi Biotherapeutics, Inc.

Gross proceeds ~$3.9M from sale of 3.325M shares at $0.65 and pre-funded warrants for 2.728M shares.
Issued Series G warrants to purchase up to 6.053M shares at $0.6954, exercisable after 6 months for 7.5 years.
Ladenburg Thalmann placement agent; 8% cash fee + 1% management; received warrants for 302,650 shares at $0.8125.
Proceeds for working capital and to advance pre-clinical and clinical programs.
Directors/officers subject to 90-day lock-up; company restricted from further issuances for 75 days (with exceptions).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.